A number of investment brokers have recently updated their price targets on shares of Carbylan Therapeutics, Inc. (CBYL). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

04/18/2016 – Carbylan Therapeutics, Inc. was downgraded to “market perform” by analysts at JMP Securities.

02/02/2016 – Carbylan Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Wedbush. They now have a USD 14 price target on the stock.

02/02/2016 – Carbylan Therapeutics, Inc. was downgraded to “market perform” by analysts at Leerink Swann. They now have a USD 1.8 price target on the stock.

06/09/2015 – Carbylan Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Northland Securities. They now have a USD 20 price target on the stock.

The share price of Carbylan Therapeutics, Inc. (CBYL) was down -0.65% during the last day of trading, with a day high of 0.76. 456609 shares were traded during the last session.

The stock’s 50 day moving average is 0.67 and its 200 day moving average is 2.05. The stock’s market capitalization is 19.61M. Carbylan Therapeutics, Inc. has a 52-week low of 0.52 and a 52-week high of 9.22.

View other investors thoughts on Carbylan Therapeutics, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.